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Photoimmunotherapy (PIT) is an emerging treatment that combines the cytotoxicity of 
photodynamic therapy with the specificity of immunotherapy. In this study, the authors demonstrated 
that administration of an affibody$infrared light$activated conjugate targeting EGFR selectively induces 
cell death in glioblastoma cells, while limiting toxicity in normal tissues. This novel approach using 
EGFR targeted PIT may alter the complex behavior of the microscopic residual tumor cells in a clinical 
scenario, resulting in better outcomes for GBM patients. 
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Glioblastomas (GBM) are high$grade brain tumours, differentially driven by alterations (amplification, 
deletion, or missense mutations) in the epidermal growth factor receptor (EGFR), that carry a poor 
prognosis of just 12$15 months following standard therapy. A combination of interventions targeting 
tumor$specific cell surface regulators along with convergent downstream signalling pathways may 
enhance treatment efficacy. Against this background, we investigated a novel photoimmunotherapy 
approach combining the cytotoxicity of photodynamic therapy with the specificity of immunotherapy.  
An EGFR$specific affibody (ZEGFR:03115) was conjugated to the phthalocyanine dye, IR700DX, which 
when excited with near$infrared light produces a cytotoxic response. ZEGFR:03115$IR700DX EGFR$
specific binding was confirmed by FACS analysis and confocal microscopy. The conjugate showed 
effective targeting of EGFR positive GBM cells in the brain. The therapeutic potential of the conjugate 
was assessed both  in GBM cell lines and spheroids by the CellTiter$Glo® assay, and  
using subcutaneous U87$MGvIII xenografts. In addition, mice were imaged pre$ and post$PIT using 
the IVIS/Spectrum/CT to monitor treatment response.  
Binding of the conjugate correlated to the level of EGFR expression in GBM cell lines. The cell 
proliferation assay revealed a receptor$dependent response between the tested cell lines. Inhibition of 
EGFRvIII+ve tumor growth was observed following administration of the immunoconjugate and 
irradiation. Importantly, this response was not seen in control tumors.  
In conclusion, the ZEGFR:03115$IR700DX showed specific uptake  and enabled imaging of EGFR 
expression in the orthotopic brain tumormodel	Moreover, the proof$of$concept   PIT study 
demonstrated therapeutic efficacy of the conjugate in subcutaneous glioma xenografts. 
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Glioblastoma (GBM) is a primary neuroepithelial tumor of the central nervous system, 
characterized by extremely aggressive clinical behavior driven by inter$ and intra$patient genomic and 
histopathological diversity.
1
 Patients with GBM have a poor prognosis, with a median overall survival 
of only 12$15 months and a 5$year survival rate of 3$5%.
2
 Currently, standard$of$care treatment 
includes maximal tumor resection followed by radiotherapy with concomitant and adjuvant systemic 
therapies e.g. temozolomide.
3
 The presence of residual tumor cells post$surgery for high$grade 
gliomas has been reported in 65% of cases and is one of the major factors contributing to GBM 
recurrence.
4,5
 Several groups have demonstrated that patients with gross total resection in the setting 
of low$ and high$grade gliomas have improved survival rates compared with patients undergoing 
subtotal resection.
6,7
 Therefore, real$time intraoperative treatment strategies are urgently needed to 
improve surgical outcomes. Fluorescence$guided surgery (FGS) combined with photodynamic 
therapy (PDT) is an interesting approach that may allow simultaneous visualization and treatment of 
infiltrating tumor cells. Recently, a number of fluorescent markers, including fluorescein sodium, 
indocyanine green (ICG), and photosensitizers (PSs), such as Photofrin, Talaporfirin sodium and 5$
aminolevulinic acid (5$ALA), have been validated in clinical trials for intraoperative delineation of 
tumor boundaries to facilitate maximal safe resection and/or eradiation of infiltrative tumor cells.
8$10
 
For instance, Stummer et al. have shown that patients who underwent FGS with 5$ALA had 
significantly improved gross total resection (65% vs 36%; 
 <0.0001) and 6$month progression$free 
survival (41% vs 21% 
 <0.0003) rates compared to patients that underwent conventional 
microsurgery under white light.
4
 In addition, Eljamel et al. have reported that FGS and repetitive 
Photofrin or 5$ALA$based PDT significantly improved median overall (12.2 vs 5.6 months for the 
control group) and progression$free survival (8.6 vs 4.8 months) in a Phase III randomised controlled 
trial in patients with GBM.
11
 Even though these PSs have been used as diagnostic and therapeutic 
agents, they lack specific cancer cell$targeting potential and, due to their 	
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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12
 Therefore, developing novel, near$infrared (NIR) molecularly$
targeted probes for intraoperative treatment of high$grade gliomas is an attractive prospect.
13,14
 
In recent years, there has been considerable interest surrounding antibody$based PDT, also 
called photoimmunotherapy (PIT), which utilizes the targeting ability of a highly specific monoclonal 
antibody (mAb) conjugated to a PS. Following excitation with NIR light, the PS generates reactive 
oxygen species (ROS), which cause cytotoxic effects exclusively in cancer cells aberrantly 
overexpressing the target receptors and sparing adjacent normal tissues.
15
 Conversely, conventional 
PDT, while effective in inducing cell death, employs non$targeted PSs that affect non$cancerous cells, 
relying entirely on physical targeting by localised optical irradiation, which limits their clinical 
application due to side$effects (e.g. cutaneous photosensitivity).
16
 Accordingly, PIT applied during 
GBM surgery could be used as an adjuvant strategy, allowing the surgeon not only to visualize 
fluorescently positive margins or microscopic residual lesions but also to eradicate residual or non$
surgically accessible tumor cells.  
Amplification of the epidermal growth factor receptor (EGFR) is the commonest genetic 
aberration, occurring in about 50% of   primary GBMs, half of which harbor the EGFRvIII 
mutation (in$frame deletion of exons 2–7) leading to constitutive and ligand$independent receptor 
activity.
17
 Thus, there is a strong rationale to develop an EGFR$targeted PIT strategy, guided by 
functional molecular imaging, which could significantly improve GBM patient management. 
Among all of the clinically useful PSs, the phthalocyanine IRDye700DX (hereafter called 
IR700DX) seems to have the most favorable chemical properties. The dye is considerably less 
sensitive to photobleaching than many other fluorochromes, has excellent water solubility and can be 
covalently conjugated to a targeted molecule via an $hydroxysuccinimide ester or maleimide.
15
 
Recent   studies have demonstrated that IR700DX$based mAb conjugates are highly specific 
for cells that express the target antigen, and have no effect on adjacent non$expressing cells.
15,18
 It 
has been found that, when the conjugate selectively binds to a target on the cell membrane and is 
exposed to NIR light, it induces rapid alterations in the cell membrane that ultimately lead to cell 
death.
18
 These promising pre$clinical findings have resulted in clinical trial initiation for the IR700DX$
cetuximab conjugate, currently in a phase I study in inoperable squamous cell carcinomas of the head 
and neck [NCT02422979]. In line with these findings, Ogawa et al. have reported that this process 
promotes the relocation of immunogenic cell death markers (e.g. calreticulin, Hsp90) to the cell 
membrane and subsequent release of immunogenic signals including ATP and HMGB1. 
While mAb$based immunoconjugates offer exquisite selectivity of binding to their designated 
targets, their poor extravasation into the tumor (due to their relatively large molecular size) hampers 
penetration into the tumor’s parenchyma, dramatically limiting the effectiveness of therapy. Therefore, 
to circumvent this concern, we have developed an IR700DX$based conjugate using low molecular 
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weight (~7 kDa) EGFR$specific affibody molecules as our targeting moiety (ZEGFR03115–IR700DX). The 
lack of di$sulphide bonds and internal cysteines, rapid folding properties and high stability of affibody 
molecules facilitate their conjugation with different radionuclides or fluorophores.
19
 Moreover, the high 
binding affinity (pM to nM range) of these molecules to wild$type EGFR, as well as EGFRvIII, their 
small size (resulting in rapid clearance from the circulation with predominantly renal excretion , 
and good tumor penetration make them ideal targeting agents for GBM therapy.
20
 
Herein, we demonstrate that administration of an affibody$infrared light$activated conjugate 
targeting EGFR selectively induces cell death in EGFR+ve glioblastoma cells, while limiting toxicity in 
normal tissues. 

	
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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
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The EGFR targeted affibody (ZEGFR:03115$Cys) and the non$specific affibody (ZTaq)were provided 
through our ongoing collaboration with AffibodyAB, Sweden. The hydrophilic IR700DX$maleimide 
used for affibody conjugation, IR700DX$NHS ester, IR700DX$carboxylate and IR800CW$maleimide 
were purchased from LI$COR Bioscience.  

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!!
The glioblastoma cell lines U87$MG and U87$MGvIII were kindly provided by Dr Frank Furnari 
(Ludwig Cancer Research, San Diego, USA) and maintained as previously described.
21
 The U251 cell 
line was courtesy of Prof. Chris Jones (The Institute of Cancer Research, London, UK). The WSz4 
primary$patient derived cell line was recently established in our lab (detailed method is provided in the 
Supplementary Information). The breast cancer cell line MCF7 was obtained from the American Type 
Tissue Culture Collection (ATCC) within the last 6 months and cultured in DMEM (Gibco, Life 
Technologies) supplemented with 10% heat$inactivated fetal bovine serum (FBS) (Gibco, Life 
Technologies). Spheroids were generated as previously described.
22
 All cell lines were grown at 37°C 
in a humidified atmosphere containing 5% CO2.  
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The conjugation of ZEGFR:03115 and ZTaq to IR700DX$maleimide are described in detail in the 
Supplementary Information. 
 

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Western blotting was performed as previously described.
23
 For antibody details see the 
Supplementary Information. 
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The specificity of the ZEGFR:03115$IR700DX binding  was investigated using flow cytometry. 
A detailed description of the protocol and data analysis is given in the Supplementary Information. 
 

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U251, U87$MGvIII and MCF7 cells were plated onto confocal glass$bottomed dishes (MatTek) at 
2×10
5
 cells/dish and incubated for 24 h. For the 3D U87$MGvIII or WSz4 cultures, cells (4×10
3
) were 
first seeded in 96$well ultra$low attachment plates (Corning® Costar®) for 72 or 120 h and then 
transferred to confocal glass$bottomed dishes. To test the specificity of conjugate binding, ZEGFR:03115$
IR700DX (1 WM) or IR700DX alone (1 WM) were added to the medium  and cells were incubated for 1, 
3 or 6 h at 37°C. To analyse the penetration of the conjugate in comparison to an antibody$based 
conjugate, U87$MGvIII spheroids were incubated with either ZEGFR:03115$IR700DX  
(500 nM), anti$EGFR targeted Antibody$FITC (500 nM) or IR700DX$maleimide alone (500 nM). 
Detailed descriptions of the procedures and image acquisition are described in the Supplementary 
Information. 
 
%
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Formalin$fixed patient$derived tumor samples, spheroids, and excised U87$MGvIII tumors, either 
following irradiation or affibody$based PIT, were embedded in paraffin, sectioned (5 m$thick slices) 
and mounted on microscope slides. Multiple sections were taken at regular intervals across each 
tumor, with sequential sections being stained with H&E (Leica), anti$Ki67 mAb (1:400, Cell Signaling 
Technology) and anti$EGFR mAb (1:400, Dako). Orthotopic tumors were snap$frozen in OCT solution 
and sectioned (10 Wm$thick slices) and mounted on microscope slides before being fixed in ice$cold 
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acetone and imaged using a Typhoon™ FLA7000 scanner (ex. 635 nm, band filter 670 nm; GE 
Healthcare Life Sciences). Following fluorescence imaging, the slides underwent IHC by staining with 
H&E (Leica), anti$Affibody® IgG mAb (1:50, Affibody) and anti$EGFR mAb (1:200, Dako).  
 
+	

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
The cytotoxic effect of ZEGFR:03115$IR700DX$based PIT  was investigated using cells grown 
as 2D and 3D cell cultures. U87$MGvIII or MCF7 cells (4×10
3
) were seeded in black 96$well plates 
with clear bottoms for 24 h. For 3D U87$MGvIII or WSz4 cultures, cells (4×10
3
) were seeded in 96$
well ultra$low attachment plates (Corning® Costar®) for 72 h or 120 h (for WSz4). On the day of the 
experiment, fresh medium containing ZEGFR:03115$IR700DX (50 nM $ 5 WM) or IR700DX (500 nM $ 5 
WM) was added for 6 h at 37°C. Cells or spheroids were then rinsed twice with phenol$red$free 
medium. Wells were irradiated in groups of nine using a red LED L690$66$60 (Marubeni). Further 
experimental details about light dosimetry are given in the Supplementary Information. Cell response 
to PIT was evaluated by the CellTiter$Glo® luminescent cell viability assay 24 h or 96 h post$
irradiation in the 2D and 3D cell cultures. In addition, formation and growth of 3D spheroids was 
monitored daily by the Celigo® image cytometry system (Nexcelom Bioscience). 
 


Detailed treatment methods are described in the Supplementary Information. All   
experiments were performed in compliance with licences issued under the UK Animals (Scientific 
Procedures) Act 1986 and following local ethical review. Studies were compliant with the United 
Kingdom National Cancer Research Institute Guidelines for Animal Welfare in Cancer Research.
24
 
Female NCr athymic mice (6 weeks) were obtained from the in$house breeding colony. Mice were 
inoculated subcutaneously (s.c.) in the top right shoulder with U87$MGvIII cells (5x10
5
) resuspended 
in PBS and mixed with BD Matrigel
TM
 Matrix (40% v/v%, BD Matrigel
TM
 Matrix, BD Bioscience). 
Details of the intracranial model are in the Supplementary Information. Orthotopic brain tumors grew 
for 11 days, at which point MR and fluorescent imaging (for details see the Supplementary 
Information) and brain extraction was performed.  
 
,!
Unless otherwise stated,   data were expressed as the Mean ± SEM and   as the 
mean ± SD. Statistical significance, sample size calculations and correlation analysis are described in 
detail in the Supplementary Information.  
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
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EGFR expression in the selected GBM cancer cell lines and the breast cancer cell line, MCF7, 
was confirmed by Western blot (WB) (Fig. 1a). The corresponding densitometric analysis of protein 
bands indicated that EGFR expression level ranged from overexpression (U87$MGEGFRvIII, 1), through 
intermediate (WSz4, 0.18) to very low (U251, 0.06; U87$MG, 0.03) and negligible expression (MCF7, 
0) (Fig. 1a). The EGFR$specific (ZEGFR:03115) and non$specific (ZTaq) affibody molecules were 
successfully conjugated via the maleimide group to IR700DX and the fluorescent$SDS$PAGE as well 
as silver staining confirmed labeling of the conjugates (Supplementary Information Fig. 1a and 1b). 
The specificity of ZEGFR:03115–IR700DX binding correlated with the expression level of EGFR as 
seen by flow cytometry and, importantly, pre$blocking the cells with 100$fold molar excess of non$
labeled affibody molecules effectively reduced the median fluorescence in all tested cell lines (Fig. 
1b). Furthermore, confocal microscopy images showed intense binding of the conjugate to the cell 
membrane of U251 cells at 4
o
C, which further confirmed binding specificity of the ZEGFR03115–IR700DX 
to EGFR (Fig. 1c, first row). At 37°C, however, the majority of the ZEGFR03115–IR700DX was uniformly 
distributed in the cytoplasm after 1 h (Fig. 1c, second row, Fig. 1e). Blocking cells with 100$fold 
excess of unlabeled affibody resulted in an almost complete absence of fluorescence from the 
corresponding conjugate, confirming that the process is receptor$mediated (Fig. 1d). Additionally, as 
expected, MCF7 cells expressing very low levels of EGFR showed negligible fluorescent signal from 
the conjugate (Fig. 1d). Cytoplasmic uptake was found to increase with incubation time, which 
indicated time$dependent internalization of the conjugate (Fig. 1e). In addition, co$staining the cells 
with the conjugate and a lysosomal marker revealed significant colocalization (Fig. 1c). Afterwards, in 
order to assess the penetration depth of the ZEGFR:03115–IR700DX, which is critical for successful PIT, 
3D U87$MGvIII or WSz4 spheroids that more closely resemble   tissue in terms of cellular 
communication, were cultured with media containing either the conjugate, IR700DX or mAbEGFR$FITC 
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(Fig. 1f, Supplementary Information Fig. 2b, Supplementary Information Movie 2$4). Importantly, 
ZEGFR:03115–IR700DX penetrated to a depth of around 200 Zm after incubation for 6 h (Fig. 1f first row, 
Fig.1g). Whereas, as expected, the antibody$based conjugate was mostly restricted to the exterior 
layers (Fig. 1f third row, Fig.1g), and hydrophilic IR700DX dye alone formed only a few fluorescent 
clusters on the very outer layer of the spheroid (Fig. 1e second row). Of note, by 72 h, H&E staining of 
the tumor spheres (400–500 Wm) did not indicate any necrosis and positive nuclear staining for Ki$67 
confirmed that the relatively large inner cores of the spheroids still contained actively proliferating cells 
(Fig. 1h, Supplementary Information Fig. 2a). 
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In order to capture cell morphologic changes induced by ZEGFR:03115–IR700DX$based PIT, U87$
MGvIII and WSz4 spheroids were imaged using a Celigo® cytometer 1, 24, 48 and 96 h (Fig. 2a) 
post$continuous irradiation with the red LED L690$66$60 for 1280 seconds (16 J/cm
2
). Phase$contrast 
images of cells grown in monolayer (2D) were taken using the Zeiss LSM700 confocal microscope to 
monitor the cells up to 2 h post$irradiation with the 639 nm laser (5 mW), (Fig. 2b) and showed very 
rapid cell swelling and bleb formation shortly after irradiation (Fig. 2b, Supplementary Information 
Movie 1), indicating rapid cell death, most likely by necrosis. Similar effects were also observed for 3D 
spheroids, but more evidently at later time points (Fig. 2a, Supplementary Information Fig. 2d). 
Necrotic cell death was further confirmed by propidium iodide (PI) staining, demonstrating that cell 
membrane integrity had been disrupted as early as 1 h post$irradiation (Fig. 2d). Furthermore, light 
activation of ZEGFR:03115–IR700DX induced ROS generation (Fig. 2e) that triggered cell death–
associated signals involved in immunogenic cell death that lead to the apparent translocation of 
calreticulin to the cellular membrane (Fig. 2c).  
To determine the phototoxicity of ZEGFR:03115–IR700DX, cells were incubated with the conjugate for 6 h 
and exposed to two different doses of NIR light. Cell viability of the 2D cultures was measured 24 h 
post$treatment and after 24 and 96 h for 3D spheroids. The percentage of cell death in targeted cells 
was significantly influenced by the dose of excitation light (Fig. 3a) and by the number of receptors 
(U87$MGvIII+ve vs MCF$7$ve), (Fig. 3a and b). U87$MGvIII cells treated with 500 nM of conjugate 
and irradiated with 16 J/cm
2
 demonstrated ~90% decrease in cell viability 24 h post$irradiation 
(CellTiter$Glo® luminescent cell viability assay). In contrast, the treatment had no effect on the 
negative control (MCF7$ve) (Fig. 3b). As expected, there was no significant cytotoxicity associated 
with exposure to ZEGFR:03115–IR700DX without NIR irradiation, IR700DX or light irradiation alone. 
Importantly, as shown in Fig. 3a, when cells were pre$incubated with 100$fold excess of non$labeled 
affibody molecules, no cell death was observed, confirming that the phototoxicity is target$specific. In 
light of these findings, cell viability following exposure to PIT was investigated in 3D cultures using 
U87$MGvIII and WSz4 spheroids. The CellTiter$Glo® luminescent assay again showed a significant 
and light dose$dependent decrease in cell viability of U87$MGvIII spheroids, with ~85% of the cells 
dying 24 h post$PIT treatment (500 nM of conjugate, 16 J/cm
2 
light exposure from the LED 
L690$66$60). WSz4 spheroid cultures were less sensitive than U87$MGvIII spheroids (Fig. 3e), 
presumably due to the lower EGFR density and likely a more resistant phenotype. In line with the 
results obtained for 2D cell cultures, there was no response when conjugate or light were used alone 
in either of the cell lines (Fig. 3c$e).  

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The specific uptake of ZEGFR:03115–IR700DX  was evaluated using mice bearing EGFR+ve 
subcutaneous U87$MGvIII xenografts (Supplementary Information Fig. 3a and b). When tumors 
reached 70$100 mm
3
, mice (n=3) were injected with the conjugate (6 g/mouse) or with the non$
specific affibody$based conjugate ZTaq$IR700DX (6 g/mouse), (Fig. 4a, Supplementary Information 
Fig. 3a). Due to high EGFR expression in normal tissues e.g. liver and submaxillary salivary gland, 10 
g of non$labeled ZEGFR:03115 was co$injected with the conjugate in order to reduce off$target EGFR 
binding. Subsequently, images were acquired 1 h post$injection, the mice were sacrificed immediately 
afterwards and their major organs extracted for further image analysis (Fig. 4b). The tumor targeting 
by the ZEGFR:03115–IR700DX estimated from image ROIs showed a prominent fluorescence signal ((3.0 
± 0.43)×10
8 
p/sec/cm
2
/sr/W/cm
2
) as early as 1 h post$conjugate administration (Fig. 4b and c). The 
tumor signal intensity after ZEGFR:03115–IR700DX injection (6 g) was calculated to be more than 6$fold 
higher than the signal measured for ZTaq$IR700DX, which confirmed the EGFR specificity of the 
affibody$based conjugate   (Fig. 4a and c).   fluorescence images demonstrated that 
amongst the non$targeted organs, the kidneys and liver exhibited the highest accumulation of the 
conjugate, producing  tumor to organ ratios of 0.85 ± 0.15 and 0.09 ± 0.02, respectively (Fig. 4b, 
Supplementary Information Fig. 3a). This high renal accumulation is due to the glomerular filtration of 
Page 6 of 20
John Wiley & Sons, Inc.
International Journal of Cancer
This article is protected by copyright. All rights reserved.
the affibody molecules followed by protein reabsorption, degradation and retention in proximal tubular 
cells. The significant liver uptake is associated with high endogenous EGFR expression. Importantly, 
in contrast to radioisotope$based imaging approaches, this does not predict toxicity because the 
conjugate is only cytotoxic within the very limited field in which NIR irradiation is delivered.  
To determine the effect of increasing the conjugate dose, 18 Wg of ZEGFR:03115–IR700DX was also 
administered which resulted in more than a two$fold increase in tumor uptake (Fig. 4c), although there 
was a decrease in tumor$to$background ratio (Fig. 4d). Of note, T:B ratios are less important when the 
conjugate has no inherent toxicity of its own (in contrast to radioisotope$based agents). Therefore, the 
conjugate dose of 18 Wg was subsequently selected for subsequent PIT studies. To select the optimal 
therapeutic window for optical irradiation in the PIT study, we next evaluated the uptake of the 
conjugate at different time points. The fluorescence signal in the tumor was greater 1 h post$injection 
and then gradually decreased over time (Fig. 4e), whereas the tumor$to$background ratios remained 
almost unchanged from 1 to 48 h (Fig. 4f). Surprisingly, when we injected the equivalent to 18 Wg 
ZEGFR:03115–IR700DX, of the highly hydrophilic IR700DX$maleimide, there was an intense tumor 
fluorescence that gradually increased over time and slow clearance was observed only after 24 h 
(Supplementary Information Fig. 4b and c). Furthermore,   images of the ~1.5 mm tumor 
sections confirmed deep penetration of the affibody molecules into the tumor tissue and high 
accumulation of the fluorophore (Supplementary Information Fig. 4d). We hypothesized that this 
uptake was due to the reactive nature of the maleimide, so we compared the pharmacokinetics (PK) 
of IR700DX with three different functional groups: IR700DX–maleimide, IR700DX$NHS ester, 
IR700DX$carboxylate. Interestingly, tumor uptake was markedly lower when administering the 
IR700DX$NHS ester and IR700DX$carboxylate and was almost completely washed out after 3 h (Fig. 
4g and h, Supplementary Information Fig. 4e), indicating that the functional group was affecting the 
PK of IR700DX and the dye itself has no preferential uptake in the tumor. To further evaluate the 
influence of the maleimide linker, we also injected an equivalent dose of IR800CW$maleimide and 
found that the agent’s behavior was very similar to the IR700DX–maleimide (Fig. 4g, second row). 
We, therefore, postulated that the increased uptake of IR700DX–maleimide is due to an association 
with blood proteins, primarily blood serum albumin, via thiols which lead to longer systemic circulation 
and preferential accumulation in the tumor. To test our hypothesis, we analyzed mouse serum 
following administration of the respective dyes and discovered that the IR700DX$maleimide dyes 
appeared to have the highest affinity for the blood proteins based on the clear and intense fluorescent 
protein bands on the SDS$PAGE gel (Fig. 4i, Supplementary Information Fig. 4a).  
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T2$weighted images confirmed an intracranial tumor located in the right side of the brain of each 
mouse (Fig. 5a). Tumor volumes determined from the MR images on the day of imaging, varied from 
40$50 mm
3
 (n = 4). The fluorescence images acquired 1 h after i.v. injection of ZEGFR:03115–IR700DX 
(18 g) revealed a fluorescent signal from the top of the skull (Supplementary Information Fig. 5a). To 
confirm that the signal originated from the brain tumor, surgical excisions were performed to remove 
the brain which subsequently was imaged  (Fig. 5b). An intense light signal was emitted from 
the site of tumor implantation (1.1×10
8 
p/sec/cm
2
/sr/W/cm
2
) (Fig. 5b). Calculated mean tumor$to$
brain ratio was 16.6 ± 7.4 (n=4) (Supplementary Information Fig. 5b). Although an equivalent dose of 
IR700DX–maleimide alone had higher tumor uptake (2.9×10
8 
p/sec/cm
2
/sr/W/cm
2
), the surrounding 
brain had large amounts of non$specific uptake and, therefore, only produced a mean tumor$to$brain 
ratio of 2.95 ± 1.07 (Supplementary Information Fig. 5b). To further demonstrate that the signal 
following ZEGFR:03115–IR700DX correlates with EGFR expression, frozen brain sections were 
prepared, imaged by immunofluorescence and subjected to IHC. Distinct receptor expression 
correlated well with the histological staining of the tumor, the fluorescence image and IHC staining of 
ZEGFR:03115–IR700DX distribution. Importantly, minimal conjugate fluorescence was present in 
surrounding mouse brain.
 
./*'01123%&''()+% 
For the PIT studies, mice bearing subcutaneous U87$MGvIII tumors were randomized into four 
groups (as in Material and Methods) and injected with ZEGFR:03115–IR700DX or IR700DX$maleimide. 
Following 1 h pre$treatment image acquisition, the mice received a light dose of 100 J/cm
2 
using the 
LED L690$66$60. Figure 6a clearly demonstrates that this dose was sufficient to photobleach the 
fluorescence signal, decreasing tumor fluorescence almost to background in the case of the 
conjugate. Interestingly, the IR700DX$maleimide fluorescence intensity not only did not photobleach, 
but rather increased in the tissues surrounding the tumor. This may be due to vessel dilation in 
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response to irradiation with the NIR light and subsequent re$accumulation of the IR700DX in the 
tumor. 
In total, each mouse received three PIT cycles, once every other day. There was a significant 
inhibition of tumor growth in mice treated with the ZEGFR:03115–IR700DX$based PIT, as well as 
IR700DX$based PDT, in comparison to the control groups that received only light or each of the 
agents alone (p  0.01; control groups vs PIT) over a period of 18 days (Fig. 6b). Of note, control 
groups had to be sacrificed earlier (~day 11) because the tumor sizes approached the limits stipulated 
in institutional guidelines and animal project licence. The advantage of PIT over PDT was highlighted 
as mice treated with the IR700DX$based PDT started to developed skin necrosis on the treated 
lesion, as early as one day after the first light exposure, whereas in PIT$treated mice the normal 
tissue was spared (Fig. 6c). Histopathological staining of tumor sections with H&E confirmed that the 
U87$MGvIII control tumors had intact tumor morphology, whereas tumors treated with a single dose of 
PIT (18 Wg ZEGFR:03115$IR700DX and an optical dose of 100 J/cm
2
) showed numerous regions of tissue 
necrosis (cells appeared to be sparse with less intense nuclei staining and vacuolar degradation), 4 h 
post$irradiation (Fig. 6d).  
 
(!

Considering the risk of recurrence of GBM if tumor cells remain following resection, any 
improvement in the intraoperative approaches that help to differentiate between tissue types and 
eradicate remaining tumor cells could substantially improve outcomes for GBM patients. To address 
this challenging problem, we evaluated an IR700DX affibody$based conjugate (ZEGFR:03115–IR700DX) 
for image$guided PIT using an EGFR+ve xenograft model of GBM. The rationale behind developing 
this particular conjugate came from recent findings showing that various disease$specific NIR 
fluorophore$based mAb probes (e.g. IR800CW$Cetuximab) have been developed for FGS of GBM.
25
 
However, the relatively large molecular size of mAbs may limit their extravasation into the GBM tumor, 
especially in areas with only partial BBB disruption. Additionally, mAbs may not reach glioma cells 
that have migrated beyond the main tumor mass. Therefore, Sexton et al. and others, have recently 
investigated EGFR$specific affibody molecules, that are ~20 times smaller than mAbs, labeled with 
IR800CW and revealed that the probe can successfully detect glioma margins.
20,26$28
 Interestingly, it 
was reported that there is a significantly higher accumulation of AffibodyEGFR$IR800CW than 
Cetuximab$IR680RD in the boundaries of glioma tumor, even though cetuximab has ~30$times 
greater affinity for EGFR than affibody molecules.
26
 Building on these findings, we went one step 
further and conjugated ZEGFR:03115 affibody molecules with the highly hydrophilic IR700DX via a 
maleimide group. Of note, IR700DX$mAb$based PIT targeting EGFR has been previously 
demonstrated to be effective in cancers such as breast, lung and bladder by Kobayashi and 
colleagues.
29$33
 We found that ZEGFR:03115–IR700DX has significant activity in inducing cell death 
selectively in EGFR+ve glioblastoma cells both  and . NIR light irradiation of U87$MGvIII 
cells following incubation with the conjugate effectively induced cellular death in a receptor$mediated 
manner. No toxicity was observed when the cells were treated with the ZEGFR:03115–IR700DX or 
IR700DX alone.  
We then asked whether exposure of ZEGFR:03115–IR700DX to NIR light results in cell membrane 
disruption shortly after treatment, since it has been previously reported that PIT leads to rapid necrotic 
cell death.
15,18
 Consistent with previous studies, we observed prominent cellular swelling, bleb 
formation and release of cellular content from U87$MGvIII cells within 2 h post$treatment initiation 
which suggested necrotic cell death. Complementary to this, at 1 h 37.8% of cells subjected to both 
light exposure and the conjugate showed positive PI staining, confirming that the integrity of the 
cellular membrane was compromised.  
Similarly to our  data with ZEGFR:03115–IR700DX,  imaging studies demonstrated that 
the conjugate penetrates deeply in the EGFR highly$expressing U87$MGvIII subcutaneous and 
orthotopic tumors, allowing for clear tumor visualization as early as 1 h post$injection. In contrast, 
intact antibodies require at least a day to achieve a high tumor$to$background ratio due to a high 
blood background, which could prove problematic for pre$surgery administration. Moreover, there was 
only negligible tumor uptake when mice were injected with the non$specific ZTaq$IR700DX affibody 
molecules that confirmed  specificity of the conjugate. Importantly, the  PIT experiments 
showed significant differences in tumor growth between U87$MGvIII tumor$bearing mice treated with 
the conjugate and control groups: (i) mice that were optically irradiated only, ii) mice that received 
ZEGFR:03115–IR700DX or saline only. While a promising start, these findings require further in$depth 
validation studies using orthotopic PDX glioma models that more precisely recapitulate the 
histopathological properties and maintain genomic characteristics of parental GBMs . It will be 
challenging, but orthotopic glioblastoma brain tumors underneath the intact skin and skull have 
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recently been unambiguously visualized using the enhanced NIR fluorescent protein IFP2.0.
34
 In 
addition, Jing et al. have reported that CD133$IR700DX mAb$based NIR$PIT extended the overall 
survival of mice with patient$derived orthotopic gliomas by a factor of two when light was applied 
through the skull following i.v. administration of the conjugate.
35
  
We also questioned whether IR700DX alone induces any anti$tumor effects. Surprisingly, and in 
contrast to our  experiments, we showed that IR700DX rapidly penetrated into the tumor mass 
and, when exposed to NIR light, inhibited tumor growth. Intrigued by these findings, we compared the 
PK of IR700DX with three different functionalities: i) maleimide (required for affibody conjugation), ii) 
N$hydroxysuccinimide (NHS) ester (the most frequently used for mAb conjugation) and, iii) 
carboxylate. All of them demonstrated distinctly different PK behaviors. The IR700DX$NHS ester and 
IR700DX$carboxylate had the highest uptake in U87$MGvIII tumor at 30 min post$injection and were 
cleared from the tumor faster than the IR700DX$maleimide (Fig. 4g, 4h). This could be attributed to 
the highly hydrolysable nature of the NHS group in aqueous solution which, , may be catalysed 
by hydrolytic enzymes present in various tissues and plasma. Conversely, maleimide functionalities 
may adhere to blood proteins with active thiol$groups remaining in the body much longer. These 
results were in agreement with previous evidence showing that the linker moiety can affect the PK of 
the probe.
36
 Even though the IR700DX$maleimide was highly effective and has the potential to be a 
useful non$targeted photosensitizer  , its high non$specific binding to serum proteins, post$
treatment skin toxicity and lack of tumor specificity will limit the probe’s utility especially for 
intraoperative PDT of brain tumors.  
In conclusion, GBM is characterized by a heterogeneous expression of amplified and mutated 
EGFR which presents a substantial challenge for the effective use of EGFR$directed therapies. 
Recently, several clinical trials using first$ and second$generation PSs have demonstrated promising 
results when used as PDT agents targeting GBM, but have not yet been approved for routine clinical 
practice. This may be attributed to the lack of specific cancer$targeting properties of these PSs and 
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Encouragingly, our   and proof$of$concept   studies clearly highlight the potential of 
eradicating EGFR+ve glioma cells using ZEGFR:03115–IR700DX$targeted PIT. The conjugate benefits 
from the small molecular weight of its targeting moiety, high specificity of binding to EGFR (wild$type 
and EGFRvIII), and emission of NIR fluorescence that permits high imaging resolution with increased 
tissue penetration depth (>2 cm). These results are particularly exciting in light of recent findings 
suggesting that EGFR amplification and mutation are initial events in the pathogenesis of GBM and 
that anti$EGFR treatments might be effective as an early therapeutic intervention.
37
 While EGFRvIII$
positive GBM cells may only represent a small percentage of total population of cancer cells, as lately 
demonstrated, they can be responsible for the survival of non$EGFRvIII$expressing tumor cells and 
the evasion of molecularly$targeted systemic therapy regimens.
38
 Therefore, killing EGFRvIII$positive 
‘linchpin’ cells using intraoperative EGFRvIII$based PIT may alter the complex behavior of the 
microscopic residual tumor cells, resulting in better outcomes for GBM patients. 

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89Varying EGFR expression in the selected cancer cell lines was confirmed by Western blot. The 
numbers in the brackets represent the relative EGFR expression as determined by densitometric 
analysis.  
89 ZEGFR:03115$IR700DX (30 nM) binding as assessed by flow cytometry in the cancer cells with 
varying EGFR expression and after blocking with 100x excess of the non$labelled ZEGFR:03115. Data are 
presented as mean ± SEM (n = 3). 
8!9 Confocal microscopy images demonstrating target$specific binding (4°C) and internalization 
(37°C) of either the ZEGFR:03115$IR700DX (1 WM), anti$EGFR$FITC antibody (25 nM for visualization 
purposes) or IR700DX alone (1 WM): 8!9 U251 cell lines (1 h incubation time), 8:9 U87$MGvIII or 
MCF7 cell lines (1$6 h incubation time), 89 U87$MGvIII spheroids (6 h incubation time). 
Hoechst
®
33342 (blue) and LysoTracker™Green DND$26 (green) were used for counterstaining. 
89 Quantification of fluorescence intensity (median fluorescence intensity) of ~8 Wm slices through 
U87$MGvIII spheroids following a 6 h incubation with ZEGFR:03115$IR700DX (500 nM) or an anti$EGFR$
FITC antibody (500 nM);Data are presented as mean ± SEM (n = 3). 
8	9H&E, EGFR and Ki67 immunostaining of U87$MGvIII spheroid (400$500 Wm) sections 72 h after 
seeding.  
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89 Incubation of U87$MGvIII spheroids with the ZEGFR:03115$IR700DX for 6 h and irradiation with  
a red LED (16 J/cm
2
) induced phototoxic cell death and disintegration of the architectural structure of 
the spheroid population.  
89 U87$MGvIII cells grown as monolayer culture showed rapid cell swelling and bleb formation (see 
arrows) as visualized by a phase contrast image 1h post ZEGFR:03115$IR700DX (red) irradiation with the 
639 nm laser on a confocal microscope. 
8!9 Following methanol fixation of U87$MGvIII cells, either treated by PIT or just irradiated, and 
staining with an anti$calreticulin$AlexaFluor488 antibody overnight (4°C), images were acquired by 
confocal microscopy. 
89 Cell membrane disruption was monitored by propidium iodide (1 Wg/mL) staining. U87$MGvIII cells 
irradiated only or treated with ZEGFR:03115$IR700DX$based PIT were analyzed by flow cytometry 1 and 
24 h post$treatment. 
89 Reactive oxygen species production was assessed using the DCFDA cellular ROS detection 
assay kit using U87$MGvIII cells treated with affibody based PIT (15 min after light exposure). The 
results were normalized to the control cells. Data are presented as mean ± SEM (n = 3). 
 
*0./*'0112%&''()+%!!	!=/*:=! 
Decrease in cell viability as assessed by the CellTiter$Glo® luminescent cell viability assay 24 or 96 h 
post$PIT in 2D cells and 3D spheroids, following 6 h incubation with the ZEGFR:03115$IR700DX and 
irradiation with a light dose of 8 or 16 J/cm
2
, was confirmed to be dose dependent and receptor 
mediated.  
89U87$MGvIII cells 24 h post$PIT.  
89MCF7 cells 24 h post$PIT.  
8!and 9U87$MGvIII spheroids 24 and 96 h post$PIT. 
89 WSz4 spheroids 96 h post$PIT.  
Data are presented as mean ± SEM (n = 3). Statistical significance in comparison to the control group 
was determined using an unpaired two$tailed Student’s test with Welch’s correction. *P ≤ 0.05, **P ≤ 
0.01, ***P ≤ 0.001, ****P ≤ 0.0001. 

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89 The U87$MGvIII tumor could easily be differentiated as early as 1 h post ZEGFR:03115$IR700DX  
(6 Wg/mouse) being intravenously injected, whereas minimal tumor uptake was observed when 
administering the same amount of the non$specific ZTaq$IR700DX.  
89 Fluorescence imaging of ZEGFR:03115$IR700DX uptake in excised tissues (1 h post$injection) and 
respective tumor$to$organ ratios. 
8!9 Mean radiant efficiency in U87$MGvIII tumors 1 h after administering either 6 Wg ZEGFR:03115$
IR700DX, 18 Wg ZEGFR:03115$IR700DX or 6 Wg of the non$specific ZTaq$IR700DX.  
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89Tumor$to$background ratio comparison when altering the injected dose of ZEGFR:03115$IR700DX. 
8and 9Fluorescence intensity and tumor$to$background ratio in the U87$MGvIII tumors over time 
after 18 WgZEGFR:03115$IR700DX  
( and 	9 Fluorescence imaging of mice bearing subcutaneous U87$MGvIII tumors. Images were 
acquired 30 min, 1 h, or 3 h post IR700DX$maleimide, IR800CW$maleimide, IR700DX$NHS Ester and 
IR700DX$carboxylate injection and the mean radiant efficiency was determined for each of the dyes.  
89 An SDS$PAGE gel of mouse blood serum imaged using the IVIS/Spectrum imaging system to 
visualize the fluorescent dyes’ association with blood proteins.  
All data are presented as mean ± SD (n ≥ 3). 

*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4?&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
89 T2$weighted MRI images of an intracranial brain tumor model 11 days post cell implantation. 89 
Photographic image of the brain and the corresponding ZEGFR:03115$IR700DX fluorescent image 
demonstrates predominant accumulation of the conjugate within the brain tumor mass.  
8!9 Transaxial brain histological sections (10 Wm) containing tumor tissue were obtained immediately 
after 1 h  image acquisition for  analysis. ZEGFR:03115$IR700DX clearly delineated tumor 
mass from the surrounding normal tissues which correlated well with H&E and EGFR staining of the 
consecutive sections.

*@
./*'0112%&''() +% 
89Fluorescence imaging of mice bearing subcutaneous U87$MGvIII tumors 1 h after injecting 18 g 
of ZEGFR:03115$IR700DX or IR700DX$maleimide (top row). Subsequently, mice were irradiated with an 
optical dose of 100 J/cm
2
 by a red LED and, immediately after, imaged again (bottom row).  
89 Tumor growth inhibition of the ZEGFR:03115$IR700DX$targeted PIT in U87$MGvIII tumors after 
administering three doses of 18 Wg of the conjugate and irradiating with 100 J/cm
2
 at days 1, 3 and 5 
in comparison to control groups. Data are presented as mean ± SD (n = 6 for each group, ** P ≤ 0.01 
as assessed by the Kruskal$Wallis test). 
8!9Visual observation of normal tissue damage in the PDT treated mice, while no skin damage was 
present in the ZEGFR:03115$IR700DX PIT mice. These were the appearances seen in all mice. 
89H&E staining of treated and untreated U87$MGvIIII tumors.

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& '(Varying EGFR expression in the selected cancer cell lines was confirmed by Western blot. The 
numbers in the brackets represent the relative EGFR expression as determined by densitometric analysis. 
'%( ZEGFR:03115'IR700DX (30 nM) binding as assessed by flow cytometry in the cancer cells with varying EGFR 
expression and after blocking with 100x excess of the non'labelled ZEGFR:03115. Data are presented as mean ± 
SEM (n = 3). ' ( Confocal microscopy images demonstrating target'specific binding (4°C) and 
internalization (37°C) of either the ZEGFR:03115'IR700DX (1 µM), anti'EGFR'FITC antibody (25 nM for 
visualization purposes) or IR700DX alone (1 µM): '( U251 cell lines (1 h incubation time), ')( U87'
MGvIII or MCF7 cell lines (1'6 h incubation time),  '(Quantification of fluorescence intensity (median 
fluorescence intensity) of ~8 µm slices through U87'MGvIII spheroids following a 6 h incubation with 
ZEGFR:03115'IR700DX (500 nM) or an anti'EGFR'FITC antibody (500 nM). Data are  U87'MGvIII or MCF7 cell 
lines (1'6 h incubation time), '( U87'MGvIII spheroids (6 h incubation time). Hoechst®33342 (blue) and 
LysoTracker™Green DND'26 (green) werpresented as mean ± SEM (n = 3). '( H&E, EGFR and Ki67 
immunostaining of U87'MGvIII spheroid (400'500 Em) sections 72 h after seeding.  

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 Incubation of U87MGvIII 
spheroids with the ZEGFR:03115IR700DX for 6 h and irradiation with a red LED (16 J/cm
2) induced phototoxic 
cell death and disintegration of the architectural structure of the spheroid population.  U87MGvIII cells 
grown as monolayer culture showed rapid cell swelling and bleb formation (see arrows) as visualized by a 
phase contrast image 1 h post ZEGFR:03115IR700DX (red) irradiation with the 639 nm laser on a confocal 
microscope.  Following methanol fixation of U87MGvIII cells, either treated by PIT or just irradiated, and 
staining with an anticalreticulinAlexaFluor488 antibody overnight (4°C), images were acquired by confocal 
microscopy. Cell membrane disruption was monitored by propidium iodide (1 µg/mL) staining. U87
MGvIII cells irradiated only or treated with ZEGFR:03115IR700DX based PIT were analyzed by flow cytometry 1 
and 24 h posttreatment.  Reactive oxygen species production was assessed using the DCFDA cellular 
ROS detection assay kit using U87MGvIII cells treated with affibody based PIT (15 min after light 
exposure). The results were normalized to the control cells. Data are presented as mean ± SEM (n = 3).  
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Decrease in cell viability as assessed by the CellTiterGlo® luminescent cell viability assay 24 or 96 h post
PIT in 2D cells and 3D spheroids, following 6 h incubation with the ZEGFR:03115IR700DX and irradiation with a 
light dose of 8 or 16 J/cm2, was confirmed to be dose dependent and receptor mediated. %& U87MGvIII 
cells 24 h postPIT. %'& MCF7 cells 24 h postPIT. %"& U87MGvIII spheroids 24 and 96 h postPIT. 
%& WSz4 spheroids 96 h postPIT. Data are presented as mean ± SEM (n = 3). Statistical significance in 
comparison to the control group was determined using an unpaired twotailed Student’s ttest with Welch’s 
correction. *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, ****P ≤ 0.0001.  
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
"!#$%"& '( The U87MGvIII tumor could easily be differentiated as 
early as 1 h post ZEGFR:03115IR700DX (6 µg/mouse) being intravenously injected, whereas minimal tumor 
uptake was observed when administering the same amount of the nonspecific ZTaqIR700DX. ')( 
Fluorescence imaging of ZEGFR:03115IR700DX uptake in excised tissues (1 h postinjection) and respective 
tumortoorgan ratios. '( Mean radiant efficiency in U87MGvIII tumors 1 h after administering either 6 µg 
ZEGFR:03115IR700DX, 18 µg ZEGFR:03115IR700DX or 6 µg of the nonspecific ZTaqIR700DX. '!( Tumorto
background ratio comparison when altering the injected dose of ZEGFR:03115IR700DX. '!( Fluorescence 
intensity and tumortobackground ratio in the U87MGvIII tumors over time after 18 µg ZEGFR:03115IR700DX 
'!#( Fluorescence imaging of mice bearing subcutaneous U87MGvIII tumors. Images were acquired 
30 min, 1 h, or 3 h post IR700DXmaleimide, IR800CWmaleimide, IR700DXNHS Ester and IR700DX
carboxylate injection and the mean radiant efficiency was determined for each of the dyes. '( An SDSPAGE 
gel of mouse blood serum imaged using the IVIS/Spectrum imaging system to visualize the fluorescent 
dyes’ association with blood proteins. All data are presented as mean ± SD (n ≥ 3).  
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	 !"!!#!!$%& T2
weighted MRI sequences of an intracranial model of brain tumor 11 days post cell implantation. %'& 
Photographic image of the brain and the corresponding fluorescent image of ZEGFR:03115IR700DX 
demonstrate predominant accumulation of the conjugate within the brain tumor mass. %& Transaxial brain 
histological sections (10 µm) containing tumor tissue were obtained immediately after 1 h  image 
acquisition for  analysis. ZEGFR:03115IR700DX clearly delineated tumor mass from the surrounding 
normal tissues which correlated well with H&E and EGFR staining of the consecutive sections.  
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	.  Fluorescence imaging of mice bearing 
subcutaneous U87MGvIII tumors 1 h after injecting 18 g of ZEGFR:03115IR700DX or IR700DXmaleimide 
(top row). Subsequently, mice were irradiated with an optical dose of 100 J/cm2 by a red LED and, 
immediately after, imaged again (bottom row).   Tumor growth inhibition of the ZEGFR:03115IR700DX
targeted PIT in U87MGvIII tumors after administering three doses of 18 g of the conjugate and irradiating 
with 100 J/cm2 at days 1, 3 and 5 in comparison to control groups. Data are presented as mean ± SD (n = 
6 for each group, ** P ≤ 0.01 as assessed by the KruskalWallis test). ! Visual observation of normal 
tissue damage in the PDT treated mice, while no skin damage was present in the ZEGFR:03115IR700DX PIT 
mice. These were the appearances seen in all mice.  H&E staining of treated and untreated U87MGvIIII 
tumors.  
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